Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms - Li, Jiannong; Bennett, Keiryn; Stukalov, Alexey; Fang, Bin; Zhang, Guolin; Yoshida, Takeshi; Okamoto, Isamu; Kim, Jae‐Young; Song, Lanxi; Bai, Yun; Qian, Xiaoning; Rawal, Bhupendra; et al. (Molecular systems biology, 2013)
Keywords: Antineoplastic Agents - pharmacology; Carbazoles - pharmacology; CD11a antigen; CD11b antigen; Cell Line, Tumor; Cell Survival - drug effects; Chromatography; Dependence; Drug resistance; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; Drug Synergism; EMBO31; EMBO37; Epidermal growth factor; epidermal growth factor receptor; Epidermal growth factor receptors; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - metabolism; Erlotinib Hydrochloride; Etiology; Experiments; Furans; Gene amplification; Gene Expression Regulation, Neoplastic; Genomics; Grb2 protein; Growth factors; Humans; interactome; Kinases; Lung cancer; Mapping; Mass spectrometry; Molecular modelling; Mutation; Neoplasm Proteins - genetics; Neoplasm Proteins - metabolism; Perturbation; Phosphorylation; Protein interaction; Protein Interaction Maps; Protein Kinase Inhibitors - pharmacology; Protein-tyrosine kinase; Proteins; Proteomics; Quinazolines - pharmacology; Scientific imaging; Staurosporine - analogs & derivatives; Staurosporine - pharmacology; Tumor cell lines; Tyrosine; tyrosine kinase inhibitor; Viability; lung cancer; interactome; tyrosine kinase inhibitor; proteomics; epidermal growth factor receptor